« Return to News | Awards & Advancement

Quintiles named a preferred provider for global PDPs

Tuesday, March 29, 2011 12:18 PM

Quintiles has been named a preferred provider to a consortium of 14 global health product development partnerships (PDPs), leveraging the combined size of their pipelines to ensure the most cost-effective use of their research and development dollars.

PDPs are not-for-profit entities that advance global health by the discovery, development and delivery of effective and affordable medicines for global neglected diseases.  The PDPs anticipate funding 128 clinical trials over the next two years. 

The members are funded, in part, by the Bill and Melinda Gates Foundation, which has committed $10 billion over the next 10 years for the poorest countries, with a portion of that funding going to the PDPs.  Funding also comes from government agencies and private entities.

Quintiles will partner with the consortium by providing one-step access to Quintiles’ global clinical development infrastructure and standards, particularly for infectious diseases such as HIV, malaria and tuberculosis.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.